Arsham Sheybani, MD
Glaucoma Specialist · Saint Louis, MONPI 1487817995
Payments from drug & device makers
Across 849 payments — averaging $1149.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$582K
- Alcon$152K
- Alcon Research LLC$88K
- Glaukos Corporation$49K
- Nova Eye, Inc.$45K
- Sight Sciences, Inc.$22K
- plus $38K from 17 others
Across 1 payment — averaging $550.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ivantis, Inc$550
What the payments were for
- Consulting fees$493,25157%
- Speaking & faculty fees$295,73534%
- Travel & lodging$49,3566%
- Food & beverage$21,7733%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 475 | $582,058 |
| Alcon | 162 | $152,262 |
| Alcon Research LLC | 40 | $87,752 |
| Glaukos Corporation | 42 | $48,535 |
| Nova Eye, Inc. | 11 | $44,552 |
| Sight Sciences, Inc. | 40 | $22,495 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $7,245 |
| Ivantis, Inc | 9 | $7,237 |
| Mobius Therapeutics, LLC | 4 | $6,700 |
| NEW World Medical,inc. | 26 | $6,040 |
| Leica Microsystems Inc. | 2 | $4,050 |
| Bausch & Lomb Americas Inc. | 7 | $3,230 |
| Katena Products, Inc. (dba Corza Medical) | 2 | $1,300 |
| Microsurgical Technology, Inc. | 1 | $750 |
| Oculus Surgical Inc. | 1 | $500 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $438 |
| Carl Zeiss Meditec, Inc. | 1 | $255 |
| Beaver-visitec International, Inc. | 1 | $184 |
| Ocular Therapeutix, Inc. | 2 | $150 |
| Boston Scientific | 1 | $113 |
| Novartis | 1 | $110 |
| Apellis Pharmaceuticals, Inc. | 1 | $48 |
| Thea Pharma Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$166,287
- XEN$158,253
- Hydrus Microstent$134,025
- DURYSTA$79,720
- OMNI(R) SURGICAL SYSTEM (US)$22,023
- iDose$15,769
- Voyager DSLT$15,142
- SION SURGICAL INSTRUMENT$14,443
- ILUX$11,200
- Clareon$11,200
- Systane$11,200
- LenSx$11,200
- Centurion$10,719
- iStent Trabecular Micro-Bypass Stent System$6,725
- Mitosol$6,700
- ARGOS$5,130
- Ahmed Glaucoma Valve$4,276
- Kahook Dual Blade$4,276
- Rocklatan$3,857
- Hydrus$3,592
How this compares
Too few glaucoma specialist providers in Missourito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 65 | $36,444 |
| LumiganBimatoprost | 74 | $31,136 |
| RhopressaNetarsudil Mesylate | 53 | $26,115 |
| Prednisolone Acetate | 356 | $10,968 |
| CombiganBrimonidine Tartrate/Timolol | 23 | $10,837 |
| Alphagan PBrimonidine Tartrate | 24 | $10,341 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 53 | $8,212 |
| VyzultaLatanoprostene Bunod | 19 | $6,780 |
| Brimonidine Tartrate | 196 | $5,797 |
| Difluprednate | 58 | $4,942 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 310 | $4,879 |
| Travoprost | 23 | $4,510 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 33 | $4,461 |
| Latanoprost | 488 | $4,329 |
| Methazolamide | 22 | $4,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Alphagan P | $582,058 | $52,314121 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $3,230 | $6,78019 claims |
| AlconSimbrinza | $152,262 | $4,00620 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Missourion file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Saint Louis
- Giovanni CampagnaSaint Louis$56K
- Erin SieckSaint Louis$44K
- Ariana LevinSaint Louis$25K
- James LiuSaint Louis$21K
- Carla SiegfriedSaint Louis$6K
- Benjamin KatzSaint Louis$4K
- Sharon SabapathypillaiSaint Louis$1K
- Sandra JohnsonColumbia$17K
- Abhinav GollaColumbia$3K
- Aaron WebelColumbia$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.